| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fb0b2ec1c62686bd1f63f161596afee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 |
| filingDate |
2018-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31ecdfe678279b1a8e56af827e77edcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2fab50ecde76786ab3437b9fb5886a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf4efa652fead182f929d0c6a2d9fe4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9136e6a7847dc58ba5a6bbc0b940ce7 |
| publicationDate |
2018-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018203594-A1 |
| titleOfInvention |
Multiplex MRM assay for evaluation of cancer |
| abstract |
ll:\szp\Interwoven\NRPortbl\DCC\SZP\16696578_1.docx-22 05/2018 The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER) proteins that are particularly advantageous for quantifying the ER proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring / Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of an ER peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. |
| priorityDate |
2011-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |